NAVLIN Daily NewsCheckout Today’s News
Spain’s Health Minister, Mónica García has underscored during a Senate meeting that the work on the royal decree on the evaluation of health technologies will be finalized in the coming weeks“We need the process of assessing the introduction of new health technologies into our healthcare system to be fully effective and efficient, and to be backed by robust scientific evidence, so that we can offer our patients the best possible guarantees,” stated GarcíaEarlier this week, Secretary of State for Health Javier Padilla confirmed that the draft had been passed with amendments by the Council of State
Speaking at this year’s Association of the British Pharmaceutical Industry's (ABPI) annual meeting in London, Dr Richard Torbett, Chief Executive of the group, argued that both the UK pharmaceutical industry and the global market are “undergoing one of the most profound shifts in a generation”Despite pointing to the hopeful tone of the ongoing themes of the ABPI meetings: “Health, growth, and renewal,” Torbett suggested “this year feels different to me,” adding that “Europe has significantly lost its global share in R&D investment, but we've lost even more of that share, and we've lost it faster, in the UK” He pointed to the U.S.’ Most Favored Nation (MFN) policy as a catalyst for this decline, suggesting that “MFN, if unchecked, risks making those trends significantly worse.” Stay tuned as NAVLIN Daily reports from the ABPI’s annual meeting today
Eli Lilly's oral weight-loss drug Foundayo (orforglipron) is set to launch in the UAE in May 2026, with supplies arriving in the first weekDr. Fatima Al Kaabi, Director-General of the Emirates Drug Establishment (EDE), described the approval as a milestone moment. “The UAE’s approval of orforglipron, being the second country in the world, is a significant step demonstrating the nation’s commitment to adopting the latest pharmaceutical innovations, particularly for people living with obesity,” she said Dr. Joseph k Joseph, Specialist in Internal Medicine, Right Health Clinics, Karama, Dubai, spoke to NAVLIN daily, said, "Some people are scared of injecting themselves even if it's once a week. So, for those with needle phobia, pills ensure better compliance, though it has to be taken daily,"
AstraZeneca CEO, Pascal Soriot has issued a stark warning over Germany’s planned healthcare cost-containment measures, saying his company may be forced to halt the launch of new medicines in the country if the proposals go ahead“It’s pure mathematics,” Soriot told Handelsblatt in an interview. “The financial impact on the business is simply too great.” This would be disastrous for German patients, he added, since many important new drugs are currently in the development and approval process, for example, treatments for cancer, metabolic diseases, and obesity. In the future, higher prices would have to be charged in Europe to support pharmaceutical innovationLast week, the Federal Minister of Health, Nina Warken, announced its draft bill, readjusting the recommendations of the Health Finance Commission’s (FKG) 66 measures to stabilize the GKV. Warken’s draft sets a rebate increase of 10.5% (instead of 14% proposed by the FKG) between January 1 and June 30, 2027, before moving into a fully dynamic adjustment mechanism from July 1, 2027
The EU’s Network of National Competent Authorities on Pricing and Reimbursement (NCAPR) has released a background paper in response to growing tensions over the U.S. Most Favoured Nation (MFN) drug pricing, warning against shifting financial burdens onto European health systems and reaffirming that “in Europe, health care is a social right”The paper notes that MFN debate is framed around two items. The first one is the perceived gap between the return on investment of pharmaceutical companies that is gained from sales in the U.S. versus the EU, a framing that has been used to argue that companies are undercompensated outside the American marketHowever, the European authorities counter that this interpretation overlooks the structural characteristics of their systems. Europe represents roughly a quarter of global pharmaceutical revenues and provides a highly attractive environment for investment and research. Although list prices are often lower, total returns remain strong, supported by universal coverage reaching 98–100% of approximately 455 million citizens, creating stable, predictable, and high-volume demand unmatched by more fragmented systems
Last week, NAVLIN Daily brought you key market access developments from across the globe. China issued its first national drug pricing guidance in more than a decade, and Germany moved closer to broad GKV cost-control reformsIn South Korea, new HIRA chief Hong Seung-kwon signaled a move toward more outcome- and value-based reimbursement, via "complete overhaul” of HTA systemMeanwhile, France’s HAS published its 2025 activity report, showing average timelines of 142 days, while higher clinical added benefit ratings (ASMR I–III) rose to 17% in 2025 from 10% in 2024
China’s groundbreaking drug price guidance document triggered a spike in innovative drug company stocks, signifying its substantial support for innovation and value-based pricingThe guidance’s consolidated, clarified approach to pricing provides certainty around returns on investment and may boost China’s status in global launch sequencingDrug developers will need to invest in real-world evidence (RWE) generation earlier to continuously verify pricing, and commercial payers (who are rising in importance) will need to be impressed by well-considered value narratives
MSN Laboratories has launched Semabest (semaglutide) in India after the drug’s patent expired in March 2026. Priced at nearly 50% less than the original brand, it’s available in a pre-filled pen made in India, offering a cheaper option for diabetes and obesity management“The product has demonstrated bioequivalence to the reference drug, with its performance further validated through phase III clinical studies conducted in direct comparison,” said Dr. Kamini Desai, head of medical affairs at MSN Laboratories Bharat Reddy, Executive Director, said, “MSN is well-positioned to ensure consistent supply, quality, and accessibility of Semabest across India"
As reported last week, China issued national-level pricing guidance for the first time in more than a decade. The document is now available on the State Council website; NAVLIN Daily is currently dissecting it to publish a full run-down in the coming days The guidance features price differentiation and stabilization for innovative drugs and expands the role of national reimbursement criteria to facilitate sustainable pricing of exclusive products, with considerations such as market scale, clinical value, rationality of the launch price, and affordabilityOther components of the document include the use of real-world evidence (RWE) to properly adjust price levels, refined centralized procurement rules, a diversified payment structure that incorporates commercial insurance, intelligent pricing oversight, raw material price management, and dynamic responses to shortages
Eli Lilly plans to bring its oral obesity drug, Foundayo (orforglipron), to India by 2026“India is an important market for Lilly, and we are committed to making orforglipron available to patients globally, including in India, subject to regulatory approvals,” said Winselow Tucker, President & GM of Lilly IndiaThe once-daily pill, designed as an alternative to injectable therapies, is expected to broaden access to obesity treatment in a price-sensitive market where demand for GLP-1 drugs is rapidly rising
650+
+99%
<24
4,000+
24x7
99.5%
